· Published by Health Canada · Official notice
This is duplicated text of a letter issued by the Therapeutic Products Directorate, Medical Devices Bureau.
Contact the company for a copy of any references, attachments or enclosures.
Important Medical Devices Safety Advisory
April 11, 2002
To:
Hospital Administrators
Director, Department of Otolaryngology
Director, Department of Orthopaedics
Director, Department of Neurosurgery
Director, Central Supply
Provincial Medical Officers of Health
Canadian Neurosurgical Society
The Canadian Orthopaedic Association
Canadian Society of Otolaryngology - Head and Neck Surgery
Dear Health Professional(s),
The purpose of this advisory is to inform you that Health Canada has suspended the medical device licence (Licence No. 14625) for Tutoplast Dura, manufactured by Tutogen Medical GmbH of Germany. The suspension means that importation and sale of this medical device is no longer permitted in Canada.
Section 11 of the Medical Devices Regulations stipulates that a medical device shall not adversely affect the health or safety of a patient, user or other person, except to the extent that a possible adverse effect of the device constitutes an acceptable risk when weighed against the benefits to the patient.
The professional staff of Medical Devices Bureau have been monitoring global events around transmissible spongiform encephalopathies, including Creutzfeldt Jakob Disease (CJD), in its various forms and has concluded that it is not possible to forecast the final impacts this may have on donor selection for cadaveric dura mater collection at this time.
Bureau staff have been engaged in dialogue with experts who are fully conversant with the use of cadaveric dura mater grafts and the availability and utility of alternatives and have concluded that suitable alternatives exist and the benefits of Tutoplast Dura over existing alternatives, in consideration of its potential risks, are not substantial enough to warrant its continued availability in Canada. These experts, which include the Canadian Neurosurgical Society (CNSS), and a leading Canadian expert in prion illness, have recommended that Tutoplast Dura no longer be sold in Canada and that a recall of all existing supplies be undertaken.
A case of confirmed CJD has been reported in the literature involving a 39 year-old in the United States who was implanted with Tutoplast Dura in 1992. The patient died in September 1998.
In summary, it is concluded that Tutoplast Dura no longer meets the requirements of Section 11 of the Regulations. The potential risks associated with the use of Tutoplast Dura outweigh the benefits associated with its use. Furthermore, this conclusion is consistent with the Health Products and Food Branch's use of precaution when considering the risk for prion illness.
The suspension of medical device licence 14625 for Tutoplast Dura is effective immediately. The Bureau is recommending that all existing supplies of Tutoplast Dura be recalled from the Canadian market by the manufacturer.
Health Canada is working with the manufacturer of Tutoplast Dura to ensure its timely removal from the Canadian market. In the interest of preventing injury to the health and safety of Canadians, we are seeking your cooperation in working with the manufacturer and Health Canada by implementing the following recommendations.
Individuals seeking additional information on the recall of this product should leave a message on the Inspectorate Hotline at 1-800-267-9675. A Health Canada official will return your call.
The manufacturer can be contacted at:
Tutogen Medical GmbH
Industriestrasse 6
91077 Neunkirchen a.B.
Germany
Tel: 011 49 9134 9988 0
Fax: 011 49 9134 9988 99
original signed by
Don Boyer A/Director,
Medical Devices Bureau
don_boyer@hc-sc.gc.ca
Tel: 613-957-4786
Any suspected adverse incident can also be reported to:
The Health Products & Food Branch Inspectorate Hotline 1-800-267-9675